Chugai reports Week 52 vamikibart data for Chugai Pharmaceutical stock

Published on 10/13/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vamikibart data covered Week 52 on October 13, 2026. Chugai Pharmaceutical stock costs EUR 34.72 at Lang & Schwarz on October 13, 2026.

Chugai reported Week 52 vamikibart data from Roche's Phase III MEERKAT and SANDCAT studies on October 13, 2026.
The latest quarter produced JPY 341.58 billion in revenue and JPY 116.33 billion in net profit.
Chugai Pharmaceutical stock was at EUR 34.72 at Lang & Schwarz on October 13, 2026, while Tokyo shares were last at JPY 6,170.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai reported Week 52 vamikibart data for Chugai Pharmaceutical stock on October 13, 2026. According to Chugai, Roche presented results from the Phase III MEERKAT and SANDCAT studies in uveitic macular edema, with sustained improvements in vision and macular thickness through Week 52.

Three pipeline dates and figures

On September 18, 2026, Chugai's investor-relations page listed approval for one FoundationOne CDx companion-diagnostic use in Japan. On September 29, 2026, Chugai entered one worldwide license agreement for SPYK04, a RAF-MEK molecular glue candidate for solid tumors, according to Fineline Cube. The current event is the October 13 vamikibart update, which places the study readout at 52 weeks.

What does Week 52 show?

The vamikibart update gives investors a clinical milestone rather than a financial forecast. Roche said the studies produced sustained vision and macular-thickness improvements through Week 52, while the treatment maintained a consistent safety profile, according to Roche on October 10, 2026.

The financial base is also substantial. In the quarter ending June 30, 2026, Chugai reported revenue of JPY 341.58 billion and net profit of JPY 116.33 billion, compared with JPY 290.01 billion and JPY 97.16 billion in the year-earlier quarter, respectively, according to The Globe and Mail. Revenue therefore rose by JPY 51.57 billion year over year, while net profit increased by JPY 19.17 billion.

Results arrive October 27

Chugai's investor-relations calendar lists its third-quarter results for October 27, 2026, followed by a financial-results conference at 6:00 p.m. Japan time. Citi maintained a Buy rating with a JPY 11,100.00 price target in a report dated October 8, 2026, according to The Globe and Mail.

Stock remains a clinical story

Chugai Pharmaceutical stock was trading at EUR 34.72 at Lang & Schwarz on October 13, 2026 at 10:01 a.m. CEST. The Tokyo Stock Exchange listing was last at JPY 6,170 on October 13, 2026 at 3:30 p.m. JST, against a 52-week range of JPY 5,974 to JPY 10,700. The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.